Abstract:Background Eukaryotic initiation factor eIF4E, an important regulator of translation, plays a crucial role in the malignant transformation, progression and chemoresistance of many human solid tumors. The overexpression of this gene has been found in a variety of human malignancies including breast carcinoma. In the present study, we attempted to explore the possibility of eIF4E as a therapeutic target for the treatment of human breast carcinoma using breast carcinoma cell line (MCF-7). Materials and methods The survivin promoter-driven eIF4E-shRNA vector was constructed on the basis of pSUPER.retro vector. Then, we established stably transfected MCF-7 and MCF210 (normal human mammary epithelial cell) cells expressing eIF4E-shRNAs or control-shRNAs. Firstly, the changes of eIF4E expression were detected by RT-PCR and Western blot assays. Next, the optimal shRNA vector (eIF4E-shRNA2) was selected to knock down eIF4E expression and investigate the effect of eIF4E-shRNA on eIF4E-regulated gene expression and cell proliferation both in vitro and in vivo. Followingly, the changes of cell cycle and apoptosis in the stably transfectants (MCF-7) were detected by flow cytometry and TUNEL methods, while we also explored possible apoptosis pathways. Finally, we investigated the effect of shRNA targeting eIF4E on the chemosensitivity of breast carcinoma cells to cisplatin in vitro and in vivo. Results Two survivin promoter-driven eIF4E-shRNA vectors were successfully constructed. eIF4E-shRNA2 but not eIF4E-shRNA1 efficiently downregulated the levels of eIF4E expression in the stably transfected MCF-7-s2 cells but not in the stably transfected MCF210-s2 cells, while MCF-7-s2 showed obvious proliferation suppression but MCF210-s2 did not. The downregulation of eIF4E expression significantly reduced the levels of VEGF, FGF-2 and cyclinD1 expression, suppressed cell growth, induced cell cycle arrest in G0/G1 phase and subsequent apoptosis by activating caspase 3 in MCF-7 cells. The results of FCM and TUNEL staining assays indicated that the classic apoptosis characters of the MCF-7 cells stably expressing eIF4E-shRNA2 manifested an apoptosis rate of 18.3%, significantly higher than those in the control groups (P < 0.05). Morever, we found that downregulation of c-IAP1, c-IAP2 and c-Myc but not Bcl-2 family proteins were involved in the apoptosis induced by eIF4E-shRNA2. In tumorigenicity assay, xenograft tumors developed from MCF-7-s2 cells in mice showed a significant slowdown in the growth speed and formation rate compared with control groups. Furthermore, we also testified that eIF4E-shRNA could synergistically enhance the cytotoxicity effects of cisplatin to MCF-7 cells both in vitro and in vivo. Conclusion Survivin promoter–driven RNA interference system could efficiently and specifically downregulate eIF4E expression in human breast carcinoma cells but not in normal human mammary epithelial cell cells. Thus, eIF4E might play an important role in chemosensitivity to cisplatin, and survivin promoter-driven RNAi targeting eIF4E can be used as adjuvant therapy for human breast carcinomas with tumor specificity and high efficacy.

Double Strand Rna-Guided Endogeneous E-Cadherin Up-Regulation Induces the Apoptosis and Inhibits Proliferation of Breast Carcinoma Cells in Vitro and in Vivo

Transcriptional Regulation of E-cadherin by Small Activating RNA: A New Double-Stranded RNA.

Up-regulation of E-cadherin by Small Activating RNA Inhibits Cell Invasion and Migration in 5637 Human Bladder Cancer Cells

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

Suppression of Migration and Invasion of PC3 Prostate Cancer Cell Line Via Activating E-Cadherin Expression by Small Activating RNA

Extensive Profiling of Circular RNAs and the Potential Regulatory Role of Circrna-000284 in Cell Proliferation and Invasion of Cervical Cancer Via Sponging Mir-506.

RNA Interference of Ecto-5′-nucleotidase (CD73) Inhibits Human Breast Cancer Cell Growth and Invasion

Antitumor effect of RNA interference on non-small cell lung cancer in vivo

[Antitumor Effect of Epidermal Growth Factor Receptor Gene Silencing].

Downregulation of Hsa_circrna_0001400 Helps to Promote Cell Apoptosis Through Disruption of the Circrna_0001400–mir-326 Sponge in Cervical Cancer Cells

Antitumor Effect of RNA Interference on Non-Small-cell Lung Cancer in Vivo

Targeting ETS1 with RNAi-based Supramolecular Nanoassemblies for Multidrug-Resistant Breast Cancer Therapy.

p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell

Tumor-specific RNAi Targeting Eif4e Suppresses Tumor Growth, Induces Apoptosis and Enhances Cisplatin Cytotoxicity in Human Breast Carcinoma Cells

Short Activating Rna (sarna) Targeting C/Ebpa Significantly Inhibits Cell Proliferation of Undifferentiated Cancer Cells.

Stable Knockdown of Estrogen Receptor Alpha by Vector-Based Rna Interference Suppresses Proliferation and Enhances Apoptosis in Breast Cancer Cells

Hsa_circrna_0006528 As a Competing Endogenous RNA Promotes Human Breast Cancer Progression by Sponging Mir‐7‐5p and Activating the MAPK/ERK Signaling Pathway

Knockdown of Eif4e Suppresses Cell Growth and Migration, Enhances Chemosensitivity and Correlates with Increase in Bax/Bcl-2 Ratio in Triple-Negative Breast Cancer Cells

Development of Double Strand RNA Mpei Nanoparticles and Application in Treating Invasive Breast Cancer

Biosynthetic Nanobubble-Mediated CRISPR/Cas9 Gene Editing of Cdh2 Inhibits Breast Cancer Metastasis